Psoriasis drug strategy hits a dead end in lab studies

A new analysis finds no scientific evidence supporting the use of histone deacetylase inhibitors—a class of drugs being explored for psoriasis treatment—in preclinical testing. The finding suggests companies and researchers may need to redirect investment toward alternative therapeutic approaches for this chronic skin condition affecting millions of patients.

Originaltitel: Lack of preclinical support for the efficacy of histone deacetylase inhibitors in the treatment of psoriasis.